¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º rV 6&:\  
V\ 1pn7~V  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ pl#2J A8  
:%&|5Ytb  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) CjFnE   
G5MoIC  
1. ICAM-1 H$D),s gv  
gc<w nm|  
2. interleukin 12(IL-12) 'dXGd.V7u  
v 3p'*81;  
3. tumor infiltrating lymphocyte L0lqm0h  
k-V3l  
4. TCR/CD3 complex LyRbD$m  
$U/|+*  
5. hematopoietin receptor family b((> ?=hh  
S4ys)!V1V  
6. individual idiotype(IdI) F<V.OFt  
 cFD3  
7. integrin n0a|GZyO]  
634OH*6  
8. colony-stimulatory factor (CSF) rv?4S`Z,x$  
c0ue[tb  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© @sdH B ./  
m[}@\y  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? \{EYkk0]  
"Snt~:W>  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ g)mjw  
Nsf>b8O  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠJ?9n4 u  
|Vo{ {)  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 0-Ga2Go9  
:Tcvj5  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) PcQ\o>0")  
HO_!/4hrU  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ yz<$?G blz  
&_$0lI DQ  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) j  Gp&P  
5wa'SexqE  
3. immunoglobulin superfamily (IgSF) -pHUC't  
~s{ V!)0  
4. selectin d:Oo5t)MN  
=D&XE*qkZ  
5. anti-idiotypic antibody (¦ÁId) U4N H9-U'  
#62*'.B4  
6. major histocompatibility complex(MHC) RT. %\)))  
tR\cS )  
7. immunotolerance =o:1Rc7J  
2YQ;Kh"S   
8. biological reponse modifier(BRM) t3b M4+n  
" ?Ux\)*  
9. immune reponse gene (Ir gene) skYHPwJdW  
VXnWY8\  
10. reshaped antibody (or reconstituted antibody) NY6;\ 7!n  
?3%r:g4  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Pm]lr|Q{I  
u2S8D uJ  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ B7wzF"  
,A5}H RW%  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? R=3|(R+kA  
 KF6N P  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 2Ab`i!#  
AyNpY_B0c  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ?  nvCp-Z$  
&;bey4_J  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ `oTV)J'~  
Y>T<Qn^D  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? +k h Tl:  
RG=i74a  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 9{}"tk5$h  
*&tTi v{^  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ k(M"k!M  
H|$ *HQm  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? oWx^_wQ-=  
J7sH]  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 3kT?Y7<fv  
/x)i}M)  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: l$ kO%E'  
K%W;-W*'  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: (w#)|9Cxm  
G^cMY$?99  
ÃâÒßѧ "[rz*[o8I  
E,dUO;  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© =7#"}%4Q  
0>46ZzxUZ  
1. CD8 cml~Oepf  
#C'E'g0  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) A^$xE6t  
cq5^7.  
3. immunoglobulin fold(Ig fold) 5wdKu,nq  
w ~"%&SNN  
4. cadherin (Ca-dependent cell adhesion moleculers) BR-wL3x b  
u\M xQIo'u  
5. idiotype-anti-idiotypic antibody immune network theory db=S*LUbl  
9 ~$E+ m(  
6. HLA class II antigen Pd& Npp3  
(`_fP.Ogb  
7. complementarity-determining region (CDR) Um4D Vg5  
$iMLT8U  
8. perforin(or pore-forming protein ,PFP) KX3A|  
uL@%M8n  
9. high affinity IL-2 receptor 9ZG:2ncdJ  
xX9snSGz  
10. artificial active immunization ^16 zZ*  
3Agyp89}Q  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© -"{g kjuv  
mhOgv\?  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ-rjQ^ze  
sekei6#fi  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 (+cZP&o  
+]z Rn  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ -'L~Y~'.  
CEBG9[|  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 61_-G#W  
,c0LRO   
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ v`jHd*&6)  
aJtpaW@  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? i7v =o#  
_ h1eW9q  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 9$U4x|n  
6O.kKhk  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ Z h9D^ I  
(i1x<  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ = &?&}pVF  
HRjbGc|[  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ?G!~&  
z}.6yHS  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© a j$& 9][  
tLN^k;w  
1. immunoglobulin gene rearrangement &Td)2Wt  
:g' 'GqGZ  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) GCiG50Z=  
sLJ]N0t  
3. flow cytometry(FCM) `?WN*__["  
9wGsHf8]  
4. carrier effect S w%6-  
mvc ;. +  
5. positive selection of T lymphocytes in thymus =Ry8E2NuM  
Zlh 2qq  
6. mouse TH1(Th1) and TH2(Th2) subsets _j3rs97@|  
%8%|6^,  
7. perforin (pore-forming protein ,PFP) x3#:C=  
BBGub?(dR  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Im!b-1  
!L q'o ?  
9. SH-2(src-homology region 2) -u<F>C  
oYA"8ei=  
10. Ab2¦Â (internal image) t']/2m.&p  
im9EV|;  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© U<=d@knH  
Mp!1xx  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ~n) |  
|6DJ5VFzD  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? W2h4ej\s  
T}1"  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠeq8faC5  
<ta{)}IN^  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ n 3&h1-  
wb(S7OsMO  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠEA1&D^nT  
;r~1TUKb  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) lxgfi@@+h  
B hx.q,X  
ÃâÒßѧרҵ£º QGV#AID3XW  
qzA_ ~=g  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ \o2l;1~  
l<4P">M!.  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? /ar0K9`c  
Vj1V;dHv  
´«È¾²¡Ñ§×¨Òµ£º n{L^W5B  
.bP8 Z =  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ YT'V/8US  
j7a }<\  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ Yy]TU} PY  
W.cc!8  
Ïû»¯×¨Òµ£º )6X-m9.X  
lc~c=17  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ g@s`PBF7`  
OvwoU=u  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 6bjZW ~  
+]-'{%-zK  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ [N~ -9  
!t~tIJ>6  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© kb"Fw:0  
"x$L 2>9  
1. Fas(CD95)/FasL )!E:  
cmU0=js.  
2. common chain of cytokine receptor qc)+T_m  
h`O$L_Z  
3 . TCR/CD3 complex B:UPSX)A  
# c1LOz  
4. negaive selection of thymocytes iR{@~JN=)  
xW9R -J \W  
5. artificial active immune \8\T TkVSq  
;@gI*i N"  
6. anti-idiotypic aQY.96yo  
lH/" 47  
7. IgSF L7GNcV]c  
(vi^ t{k  
8. Integrin dQ_'8 )  
hR2 R  
9. chemokine 2sG1Hox  
4, Vx3QFZ  
10. B7/CD28 ^!k_"C)B  
n!X%i+|4x  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Er$&}9G+-  
TPkP5w  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ F2Ny=H &G  
' Gx\  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ |FlB#  
a5pM~.]  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ ~+BU@PHv  
|na9I6  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ Vi'7m3&  
9<P%?Q  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ .Q@]+&`|}i  
XPt>klf  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ TI"Ki$jC  
p`U#  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© lY,9bSF$  
"OkZ [E)  
1. B7/CD28 rXTdhw?+  
 } MP_  
2. Th1 subset hmb=_W  
m)6-D- &7  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© qf [J-"o  
PT&qys 2k  
4. antibody affinity maturation XIM?$p^  
ci 22f w0  
5. AP-1 fG.6S"|M  
es+ZPX>Y  
6. single chain variable fragment£¨ScFv£© QOJ5  
m,w^,)  
7. NK cell receptor 7(LB}  
5Go@1X]I  
8. Zinkernagel-Doherty phenomenon Yc5) ^v  
DC$> 5FDv  
9. Ig fold $Nj' _G\}  
w>RwEU+w=@  
10. CD40/CD40L << YH4}wZ  
poqNiOm4%  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© '^2bC  
\C1`F [d_  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ a'my0 m  
+~lPf.  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ k>\s6  
2)q$HUIX  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Y#U0g|UDn  
de"+ABR  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ P2U[PO  
0qN?4h)7  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 8&#)}A}x  
XJ7mvLM;  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ k]A$?C0Q<%  
:C#(yp  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ RUV:   
il:RE8  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© KKwJ=za  
1tCe#*|95  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© M >s,I^  
FWpb5jc)3  
1.Co-stimulators (or co-stimulating molecules) nrz2f7d$  
'c/Z W  
2.NK-kB I h 19&D  
hr GfA  
3.Immunoglobulin superfamily 9m2Yrj93  
Sh o] ~)XX  
4.antigen-presenting cell (APC) R94 ID@L F  
roWg~U(S  
5.death domain 0BHSeO,  
 )9$>i5l  
6.CCR and CXCR ,*{9 g6  
<0^L L  
7.Lectin (or mitogen) J [ 4IO  
soB5sFt&]  
8.Clusters of differentiation, CD) (n~GKcA  
3Qoa ?*  
9.B7 family vip& b}u  
xrC b29{  
10.Cytotoxic T lymphocyte, CTL) "_36W X  
5R"(4a P  
11.IL-15 and IL-15 receptor (IL-15R) ugMf pT)  
<+${ gu?^  
12.MHC restriction jM|-(Es. )  
LuUfdzH  
13.Affinity-chromatography D= LLm$y  
'6W|,  
14.Cyctosprin A, CsA q8e34Ly7  
m%G:|`f7  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) _^"0"<,  
V sMTzGr  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© zz~AoX7V6  
8 ,<F102(  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 f6-OR]R5  
HOrD20  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 9H4NvB{  
u!WjG@  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ NU?05sF  
Fj~,>   
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ^u[n!R\  
DU>#eR0G  
ÃâÒßѧרҵ£º \9}RAr#2]N  
/ MUa b*h  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ U4hFPK<  
2PrUI;J$  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ "TboIABp:H  
 UX& ?^]  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ >SR! *3$5  
@3F4Lg6H|  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) tEXY>=  
AvS<b3EoN  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) c0%.GcF0{  
"}(g3Iy  
1. ADCC(antibody dependent cell-mediated cytotoxicity) 8 qY\T0  
H3{FiB]  
2. »·æß¾úËØ(cyclosporin) 9n rH 6]  
@ !UuK;  
3. KIR(killer cell inhibitory receptor) ,XJ Xw(LM  
 *Fe  
4. HLDA(human leucocyte differentiation antigen)  @{|vW  
L(bYG0ZI5C  
5. Interleukin 18(IL-18) Qg\{d)X[N  
6pHn%yE*  
6. ÕûºÏËØ(integrin) u\9t+wi}<  
`?fY!5BA  
7. Fas/FasL 5A~lu4-q  
-t:~d:  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) eiJ 13`T  
X?'v FC  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) xElHYh(\  
!BocF<UE  
10. Th1/Th2 <ETR6r  
{O4y Y=G  
11. »ùÒòÒßÃç(DNAÒßÃç) U;l!.mze  
M :4N'#`  
12. chemokines and chemokine receptor 9HjtWQn  
># {,(8\  
13. ÃâÒßÄÍÊÜ }52]  
Y] ZNAR  
14. ¹²´Ì¼¤·Ö×Ó ]W-7 U_  
)9.i'{{ 0  
15. ËÀÍö½á¹¹Óò(death domain) m3cO { 1I  
phT|w H  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) OqaVp/,  
&rcC7v K9  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?  o IUjd  
Zi0B$3iOb  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠGuc~] B  
ymIjm0jVh  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î eC9nOwp]xH  
8op,;Z7Y  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ HW{si]~q  
L=7 U#Q/DE  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå lcv&/ A  
$6(,/}==0  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ MQ9Nn|4  
;Y&<psQeb  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) $*%ipD}f  
"|2|Vju%  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ * 5H  
bVB_KE  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ )9^0Qk' ]  
'^T Q Ubw  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»